1. Home
  2. AKR vs AGIO Comparison

AKR vs AGIO Comparison

Compare AKR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKR
  • AGIO
  • Stock Information
  • Founded
  • AKR 1993
  • AGIO 2007
  • Country
  • AKR United States
  • AGIO United States
  • Employees
  • AKR N/A
  • AGIO N/A
  • Industry
  • AKR Real Estate Investment Trusts
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • AKR Real Estate
  • AGIO Health Care
  • Exchange
  • AKR Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • AKR 2.2B
  • AGIO 2.0B
  • IPO Year
  • AKR 1993
  • AGIO 2013
  • Fundamental
  • Price
  • AKR $20.95
  • AGIO $29.30
  • Analyst Decision
  • AKR Buy
  • AGIO Buy
  • Analyst Count
  • AKR 4
  • AGIO 8
  • Target Price
  • AKR $23.00
  • AGIO $56.57
  • AVG Volume (30 Days)
  • AKR 1.2M
  • AGIO 593.1K
  • Earning Date
  • AKR 04-28-2025
  • AGIO 05-01-2025
  • Dividend Yield
  • AKR 3.64%
  • AGIO N/A
  • EPS Growth
  • AKR N/A
  • AGIO N/A
  • EPS
  • AKR 0.19
  • AGIO 11.64
  • Revenue
  • AKR $375,840,000.00
  • AGIO $36,498,000.00
  • Revenue This Year
  • AKR N/A
  • AGIO $50.61
  • Revenue Next Year
  • AKR $24.22
  • AGIO $223.79
  • P/E Ratio
  • AKR $110.47
  • AGIO $2.52
  • Revenue Growth
  • AKR 13.20
  • AGIO 36.07
  • 52 Week Low
  • AKR $16.14
  • AGIO $27.14
  • 52 Week High
  • AKR $26.29
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • AKR 35.58
  • AGIO 35.86
  • Support Level
  • AKR $20.81
  • AGIO $30.00
  • Resistance Level
  • AKR $21.50
  • AGIO $32.90
  • Average True Range (ATR)
  • AKR 0.46
  • AGIO 1.25
  • MACD
  • AKR -0.01
  • AGIO -0.15
  • Stochastic Oscillator
  • AKR 21.61
  • AGIO 20.80

About AKR Acadia Realty Trust

Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company's portfolios are located primarily in metropolitan areas of the United States. The company operates through three segments: core portfolio, which consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon and generates the majority of total revenue; funds, which comprises the funds launched by the trust; and structured financing, which consists of notes receivable and related interest income.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: